{"log_id": 1599587810768521709, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 0.030948, "average": 0.817501, "min": 0.64158}, "location": {"width": 54, "top": 93, "height": 29, "left": 1121}, "words": "因家"}, {"probability": {"variance": 0.00158, "average": 0.990055, "min": 0.71771}, "location": {"width": 828, "top": 203, "height": 28, "left": 198}, "words": "射伊立替康2mg/kg和25mg/kg,然后恢复91周的试验(大鼠静脉注射伊立替康25mg/kg后,其"}, {"probability": {"variance": 0.000681, "average": 0.987299, "min": 0.878482}, "location": {"width": 783, "top": 249, "height": 30, "left": 242}, "words": "和AUC分别约相当于人每周给药125mg/m2后的7倍和1.3倍),结果显示,子宫喇叭口处子"}, {"probability": {"variance": 0.004397, "average": 0.983642, "min": 0.622316}, "location": {"width": 643, "top": 300, "height": 27, "left": 199}, "words": "宫内膜间质息肉和子宫内膜间质肉瘤发生率的增加有明显的剂量依赖性"}, {"probability": {"variance": 8e-06, "average": 0.996933, "min": 0.99217}, "location": {"width": 208, "top": 372, "height": 61, "left": 203}, "words": "【药代动力学"}, {"probability": {"variance": 0.00096, "average": 0.992449, "min": 0.795707}, "location": {"width": 804, "top": 424, "height": 29, "left": 219}, "words": "伊立替康和SN-38其活性代谢产物)的药代动力学特性在I期临床试验中进行了研究,60"}, {"probability": {"variance": 0.001666, "average": 0.984556, "min": 0.813476}, "location": {"width": 828, "top": 472, "height": 30, "left": 196}, "words": "例患者接受了推荐剂量方案的药物治疗,即30分钟静脉滴注本品100750mg/m2伊立替康的"}, {"probability": {"variance": 8e-05, "average": 0.99739, "min": 0.943691}, "location": {"width": 826, "top": 520, "height": 30, "left": 196}, "words": "动力学曲线是非剂量依赖性的。在临床研究中接受不同伊立替康给药方案的患者,其药代动"}, {"probability": {"variance": 2e-06, "average": 0.998689, "min": 0.996214}, "location": {"width": 109, "top": 569, "height": 27, "left": 197}, "words": "力学均相似"}, {"probability": {"variance": 0.000105, "average": 0.997104, "min": 0.94036}, "location": {"width": 817, "top": 617, "height": 29, "left": 196}, "words": "其血浆衰减模式既是二室的又是三室的。三室模型中平均血浆半衰期在第一阶段为12分钟"}, {"probability": {"variance": 9.7e-05, "average": 0.995654, "min": 0.941357}, "location": {"width": 819, "top": 666, "height": 29, "left": 196}, "words": "第二阶段为2.5小时,终末消除阶段为14.2小时。在使用推荐剂量350mg/m静滴结束时伊立"}, {"probability": {"variance": 0.006645, "average": 0.967786, "min": 0.548075}, "location": {"width": 820, "top": 714, "height": 29, "left": 195}, "words": "替康和SN-38达到血浆峰浓度,分别为7.7μg/ml,56ng/ml,其曲线下面积分别为34μgh/ml"}, {"probability": {"variance": 0.007674, "average": 0.976356, "min": 0.555605}, "location": {"width": 821, "top": 763, "height": 28, "left": 200}, "words": "41ng.h/ml,其稳态分布容积很大,并保持相对稳定,为剂量的函数,平均为157L/m2。机"}, {"probability": {"variance": 0.000378, "average": 0.992114, "min": 0.890303}, "location": {"width": 815, "top": 808, "height": 33, "left": 196}, "words": "体总清除率平均值为15L/h/m2,且在同一患者的不同治疗周期保持稳定。SN-38在不同个体"}, {"probability": {"variance": 0, "average": 0.99952, "min": 0.999003}, "location": {"width": 235, "top": 858, "height": 26, "left": 194}, "words": "其药物代谢参数变化很大"}, {"probability": {"variance": 0.002314, "average": 0.988793, "min": 0.680594}, "location": {"width": 829, "top": 905, "height": 35, "left": 193}, "words": "伊立替康和SN-3824小时平均尿排泄率分别为使用剂量的19.9%和0.25%。关于伊立替康药"}, {"probability": {"variance": 0.000121, "average": 0.995749, "min": 0.941752}, "location": {"width": 823, "top": 953, "height": 32, "left": 194}, "words": "代动力学的II期临床试验在72例肿瘤患者中进行。计算出的药代动力学参数与I期研究的参"}, {"probability": {"variance": 0.001453, "average": 0.979394, "min": 0.903192}, "location": {"width": 108, "top": 1003, "height": 26, "left": 194}, "words": "数十分接近"}, {"probability": {"variance": 0.002989, "average": 0.984703, "min": 0.682214}, "location": {"width": 824, "top": 1048, "height": 34, "left": 193}, "words": "体外实验中,伊立替康和SN-38的血浆蛋白结合率分别约为65%和95%。当患者的胆红素在"}, {"probability": {"variance": 0.003487, "average": 0.979614, "min": 0.670899}, "location": {"width": 821, "top": 1098, "height": 29, "left": 193}, "words": "正常值上限的1.5-3倍时,伊立替康清除率降低约40%。在这些患者中给予伊立替康200mg/m3"}, {"probability": {"variance": 0.000636, "average": 0.99217, "min": 0.876839}, "location": {"width": 825, "top": 1145, "height": 34, "left": 192}, "words": "时,其血浆药物浓度与正常肝功能的癌症患者给予伊立替康350mg/m2时相同。与5-氟尿嘧啶"}, {"probability": {"variance": 2e-06, "average": 0.998779, "min": 0.994455}, "location": {"width": 432, "top": 1196, "height": 27, "left": 192}, "words": "/亚叶酸合用,不改变伊立替康药代动力学特性"}, {"probability": {"variance": 0.000536, "average": 0.993852, "min": 0.864889}, "location": {"width": 824, "top": 1243, "height": 34, "left": 192}, "words": "使用本品后,主要毒副作用的强度(如白细胞减少症和腹泻)与母体药物和其代谢产物SN-38"}, {"probability": {"variance": 0.000113, "average": 0.996302, "min": 0.93412}, "location": {"width": 825, "top": 1292, "height": 34, "left": 191}, "words": "的曲线下面积有关。在单药治疗中,血液学毒性(白细胞及中性粒细胞下降至最低点)或腹"}, {"probability": {"variance": 0.004398, "average": 0.98634, "min": 0.623474}, "location": {"width": 600, "top": 1340, "height": 33, "left": 190}, "words": "泻的程度与伊立替康和其代谢产物SN-38的曲线下面积值显著相关"}, {"probability": {"variance": 7e-06, "average": 0.997942, "min": 0.99342}, "location": {"width": 74, "top": 1419, "height": 26, "left": 197}, "words": "【贮藏】"}, {"probability": {"variance": 0, "average": 0.999469, "min": 0.998919}, "location": {"width": 151, "top": 1469, "height": 26, "left": 211}, "words": "遮光,密闭保存"}, {"probability": {"variance": 0, "average": 0.999696, "min": 0.999386}, "location": {"width": 78, "top": 1544, "height": 26, "left": 195}, "words": "【包装】"}, {"probability": {"variance": 0.000411, "average": 0.992465, "min": 0.925561}, "location": {"width": 246, "top": 1594, "height": 29, "left": 209}, "words": "棕色玻璃瓶装,每小盒1支"}], "language": 3}